Bortezomib- is an anti-cancer drug and the first therapeutic proteasome inhibitor

Bortezomib is an anti-cancer drug and the first therapeutic proteasome inhibitor to be used in humans. Proteasomes are cellular complexes that break down proteins.

Bortezomib- is an anti-cancer drug and the first therapeutic proteasome inhibitor

Bortezomib; Velcade; PS-341; Ps 341; LDP-341

Bortecad, Bortenat, Bortrac, Bortrac, Borviz, Egybort, Mibor, Myezom, Ortez, Velcade

[(1R)-3-methyl-1-[(2S)-3-phenyl-2-(pyrazin-2-ylformamido) propanamido] butyl] boronic acid

This inhibits the mammalian 26S proteasome. 

As directed by physician

For treatment of multiple myeloma and mantle cell lymphoma.For treatment of multiple myeloma and mantle cell lymphoma.

Asthenic conditions; pyrexia; GI disturbances, anorexia; peripheral neuropathy; dehydration; thrombocytopenia, anaemia; neutropenia, hypotension; cardiac disorders; bone and body pain; cough, dyspnoea; rash, oedema; hypersensitivity reactions; painful or difficult urination, pneumonia, pyrexia, diarrhea, vomiting, dehydration and nausea.

• Concurrent use of antihypertensive drugs increases the chance of hypotension.
• Concurrent use of amiodarone, antivirals, isoniazid, nitrofurantoin, and statins may increase the chance of peripheral neuropathy. 

• Hypersensitivity.
• Child.
• Pregnancy and lactation

Molecular weight

384.237

Molecular formula

C19H25BN4O4

CAS number

179324-69-7

Precautions

• Monitor for symptoms of peripheral neuropathy.
• History of syncope, orthostatic hypotension; Hepatic or renal impairment; dehydration. Impairs ability to drive or operate machinery.
• Monitor closely the blood glucose levels in patients receiving oral antidiabetic agents.